Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Authors:

Abstract
Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.
Funding Information
  • No funding

This publication has 10 references indexed in Scilit: